Chronic Exposure to MPTP as a Primate Model of Progressive Parkinsonism: A Pilot Study with a Free Radical Scavenger
Identifieur interne : 001F19 ( Main/Exploration ); précédent : 001F18; suivant : 001F20Chronic Exposure to MPTP as a Primate Model of Progressive Parkinsonism: A Pilot Study with a Free Radical Scavenger
Auteurs : P. J. Blanchet [États-Unis] ; S. Konitsiotis [États-Unis] ; K. Hyland [États-Unis] ; L. A. Arnold [États-Unis] ; K. D. Pettigrew [États-Unis] ; T. N. Chase [États-Unis]Source :
- Experimental Neurology [ 0014-4886 ] ; 1998.
English descriptors
Abstract
The development of a validated primate model of progressive parkinsonism is a critical step in the evaluation of drugs that might halt or slow progression of Parkinson's disease. In this pilot study, we gradually exposed 14 cynomolgus monkeys to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), at a weekly dose of 0.5 mg/kg s.c. for 10 weeks, to determine their probability of not reaching a predetermined endpoint on a disability scale by Kaplan–Meier analysis. Four other MPTP-exposed animals were coadministered the potent free radical scavenger 7-hydroxy-1-[4-(3-methoxyphenyl)-1-piperazinyl]acetylamino-2,2,4,6- tetramethylindan (OPC-14117) as a single oral daily dose of 0.6 g/kg, starting 2 weeks before MPTP initiation. The risk of reaching endpoint by week 10 was 79% and mean time before reaching endpoint was 6 weeks. Global motor activity, recorded in a subset of animals using a portable activity monitor, declined following the first MPTP dose and never recovered. Several cerebrospinal fluid indices of central monoamine metabolism collected by suboccipital puncture at 0, 5, and 10 weeks, including HVA, DOPAC, and tetrahydrobiopterin but not MHPG, were found to be “trait” markers for MPTP exposure, whereas CSF DOPAC and tetrahydrobiopterin constituted potential “state” markers for reaching endpoint. The antioxidant OPC-14117 did not protect against MPTP-induced parkinsonism. Further attempts to validate this incremental model of neurotoxin-induced parkinsonism as a predictor of patient responses to putative neuroprotective agents appear warranted.
Url:
DOI: 10.1006/exnr.1998.6906
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chronic Exposure to MPTP as a Primate Model of Progressive Parkinsonism: A Pilot Study with a Free Radical Scavenger</title><author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name></author><author><name sortKey="Konitsiotis, S" sort="Konitsiotis, S" uniqKey="Konitsiotis S" first="S." last="Konitsiotis">S. Konitsiotis</name></author><author><name sortKey="Hyland, K" sort="Hyland, K" uniqKey="Hyland K" first="K." last="Hyland">K. Hyland</name></author><author><name sortKey="Arnold, L A" sort="Arnold, L A" uniqKey="Arnold L" first="L. A." last="Arnold">L. A. Arnold</name></author><author><name sortKey="Pettigrew, K D" sort="Pettigrew, K D" uniqKey="Pettigrew K" first="K. D." last="Pettigrew">K. D. Pettigrew</name></author><author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T. N." last="Chase">T. N. Chase</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B0E089040A4A417DA9F24E19F4425E6F43BBA470</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1006/exnr.1998.6906</idno><idno type="url">https://api.istex.fr/document/B0E089040A4A417DA9F24E19F4425E6F43BBA470/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002809</idno><idno type="wicri:Area/Main/Curation">002464</idno><idno type="wicri:Area/Main/Exploration">001F19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Chronic Exposure to MPTP as a Primate Model of Progressive Parkinsonism: A Pilot Study with a Free Radical Scavenger</title><author><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MarylandKimberly H. Courtwright and Joseph W. Summers Institute of Metabolic Disease, Baylor University Medical Center, Dallas, TexasDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TexasDivision of Epidemiology and Research Services, National Institute of Mental Health, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Konitsiotis, S" sort="Konitsiotis, S" uniqKey="Konitsiotis S" first="S." last="Konitsiotis">S. Konitsiotis</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MarylandKimberly H. Courtwright and Joseph W. Summers Institute of Metabolic Disease, Baylor University Medical Center, Dallas, TexasDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TexasDivision of Epidemiology and Research Services, National Institute of Mental Health, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Hyland, K" sort="Hyland, K" uniqKey="Hyland K" first="K." last="Hyland">K. Hyland</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MarylandKimberly H. Courtwright and Joseph W. Summers Institute of Metabolic Disease, Baylor University Medical Center, Dallas, TexasDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TexasDivision of Epidemiology and Research Services, National Institute of Mental Health, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Arnold, L A" sort="Arnold, L A" uniqKey="Arnold L" first="L. A." last="Arnold">L. A. Arnold</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MarylandKimberly H. Courtwright and Joseph W. Summers Institute of Metabolic Disease, Baylor University Medical Center, Dallas, TexasDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TexasDivision of Epidemiology and Research Services, National Institute of Mental Health, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Pettigrew, K D" sort="Pettigrew, K D" uniqKey="Pettigrew K" first="K. D." last="Pettigrew">K. D. Pettigrew</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MarylandKimberly H. Courtwright and Joseph W. Summers Institute of Metabolic Disease, Baylor University Medical Center, Dallas, TexasDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TexasDivision of Epidemiology and Research Services, National Institute of Mental Health, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T. N." last="Chase">T. N. Chase</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MarylandKimberly H. Courtwright and Joseph W. Summers Institute of Metabolic Disease, Baylor University Medical Center, Dallas, TexasDepartment of Neurology, University of Texas Southwestern Medical Center, Dallas, TexasDivision of Epidemiology and Research Services, National Institute of Mental Health, National Institutes of Health, Bethesda</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Experimental Neurology</title><title level="j" type="abbrev">YEXNR</title><idno type="ISSN">0014-4886</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1998">1998</date><biblScope unit="volume">153</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="214">214</biblScope><biblScope unit="page" to="222">222</biblScope></imprint><idno type="ISSN">0014-4886</idno></series><idno type="istex">B0E089040A4A417DA9F24E19F4425E6F43BBA470</idno><idno type="DOI">10.1006/exnr.1998.6906</idno><idno type="PII">S0014-4886(98)96906-0</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0014-4886</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MPTP</term><term>Parkinson's disease</term><term>antioxidant.</term><term>monkeys</term><term>neuroprotection</term><term>oxidative stress</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The development of a validated primate model of progressive parkinsonism is a critical step in the evaluation of drugs that might halt or slow progression of Parkinson's disease. In this pilot study, we gradually exposed 14 cynomolgus monkeys to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), at a weekly dose of 0.5 mg/kg s.c. for 10 weeks, to determine their probability of not reaching a predetermined endpoint on a disability scale by Kaplan–Meier analysis. Four other MPTP-exposed animals were coadministered the potent free radical scavenger 7-hydroxy-1-[4-(3-methoxyphenyl)-1-piperazinyl]acetylamino-2,2,4,6- tetramethylindan (OPC-14117) as a single oral daily dose of 0.6 g/kg, starting 2 weeks before MPTP initiation. The risk of reaching endpoint by week 10 was 79% and mean time before reaching endpoint was 6 weeks. Global motor activity, recorded in a subset of animals using a portable activity monitor, declined following the first MPTP dose and never recovered. Several cerebrospinal fluid indices of central monoamine metabolism collected by suboccipital puncture at 0, 5, and 10 weeks, including HVA, DOPAC, and tetrahydrobiopterin but not MHPG, were found to be “trait” markers for MPTP exposure, whereas CSF DOPAC and tetrahydrobiopterin constituted potential “state” markers for reaching endpoint. The antioxidant OPC-14117 did not protect against MPTP-induced parkinsonism. Further attempts to validate this incremental model of neurotoxin-induced parkinsonism as a predictor of patient responses to putative neuroprotective agents appear warranted.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Blanchet, P J" sort="Blanchet, P J" uniqKey="Blanchet P" first="P. J." last="Blanchet">P. J. Blanchet</name></region><name sortKey="Arnold, L A" sort="Arnold, L A" uniqKey="Arnold L" first="L. A." last="Arnold">L. A. Arnold</name><name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T. N." last="Chase">T. N. Chase</name><name sortKey="Hyland, K" sort="Hyland, K" uniqKey="Hyland K" first="K." last="Hyland">K. Hyland</name><name sortKey="Konitsiotis, S" sort="Konitsiotis, S" uniqKey="Konitsiotis S" first="S." last="Konitsiotis">S. Konitsiotis</name><name sortKey="Pettigrew, K D" sort="Pettigrew, K D" uniqKey="Pettigrew K" first="K. D." last="Pettigrew">K. D. Pettigrew</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:B0E089040A4A417DA9F24E19F4425E6F43BBA470
|texte= Chronic Exposure to MPTP as a Primate Model of Progressive Parkinsonism: A Pilot Study with a Free Radical Scavenger
}}
| This area was generated with Dilib version V0.6.23. |  |